Company profile: CiVi Biopharma
1.1 - Company Overview
Company description
- Provider of clinical-stage biotechnology research and development focused on novel cardiovascular therapies, including CiVi 008, an oral PCSK9-targeting treatment to lower LDL cholesterol and prevent atherosclerotic cardiovascular disease, and CiVi 030, an intravenous iloprost formulation for severe frostbite with vasodilator, platelet inhibitor, anti-inflammatory, and anti-fibrotic effects.
Products and services
- Clinical-Stage Cardiovascular R&D: Executes clinical-stage research and development in cardiovascular as a biotechnology company whose mission is to create novel cardiovascular (clinical-stage)
- CiVi 030: An intravenous formulation of iloprost for severe frostbite that dilates vessels, inhibits platelets, and reduces inflammation and fibrosis, delivering vasodilator, platelet inhibitor, anti-inflammatory, anti-fibrotic effects (intravenous)
- CiVi 008: An oral PCSK9-targeting therapy for hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, lowering LDL cholesterol through PCSK9 inhibition to reduce circulating LDL levels (oral)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CiVi Biopharma
Terumo Aortic
HQ: United Kingdom
Website
- Description: Provider of vascular and cardiovascular grafts and aortic repair solutions, designing and manufacturing sealed woven and knitted polyester grafts and devices for surgical, endovascular and hybrid aortic repair. Offerings include Thoraflex Hybrid, RelayPro for thoracic aortic disease, TREO for abdominal aortic aneurysms, and cardiothoracic and thoracoabdominal surgical designs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Terumo Aortic company profile →
Cordis
HQ: United States
Website
- Description: Provider of less invasive treatments for vascular disease as a Johnson & Johnson company, and developer/manufacturer of stents, catheters, and guidewires. Offerings include SELUTION SLR Drug-Eluting Balloon for controlled, sustained sirolimus release; BRITE TIP Guiding Catheter; MYNX CONTROL Vascular Closure Device; RAIN Sheath Transradial thin-walled introducer; and RAILWAY Sheathless Access System.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cordis company profile →
Scanadu
HQ: United States
Website
- Description: Provider of mobile medical devices, including Scanadu Scout for checking vital signs and Scanaflo, an at-home urine analysis test with results viewable on a smartphone.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scanadu company profile →
Perouse Medical
HQ: France
Website
- Description: Provider of medical devices for the treatment of cardiovascular pathologies and for vascular access for intravenous therapies, specializing in long-term vascular access; part of the Vygon Group, a French group specialized in single-use medical devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perouse Medical company profile →
R3 Vascular
HQ: United States
Website
- Description: Provider of medical devices for peripheral artery disease, including the MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS), which maintains vessel support, delivers sirolimus to prevent restenosis, and gradually resorbs into tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full R3 Vascular company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CiVi Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CiVi Biopharma
2.2 - Growth funds investing in similar companies to CiVi Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CiVi Biopharma
4.2 - Public trading comparable groups for CiVi Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →